Targeting the JAK/STAT-3 Pathway Signaling Axis in Glioma

靶向胶质瘤中的 JAK/STAT-3 通路信号轴

基本信息

  • 批准号:
    8237478
  • 负责人:
  • 金额:
    $ 30.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-03-01 至 2017-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Glioblastoma (GBM) is a malignancy of the central nervous system that is nearly universally fatal. Constitutive activation of tyrosine phosphorylation signaling pathways is one hallmark of cancers, including GBMs. GBMs show elevated levels and persistent activation of Signal Transducer and Activator of Transcription-3 (STAT-3), a transcription factor that drives expression of genes that regulate anti-apoptotic responses, angiogenesis, cell proliferation and signal transduction. Importantly, STAT-3 was recently shown to be a master regulator of GBM aggressiveness. Janus Kinase 1 (JAK1) and JAK2, tyrosine kinases critical for STAT-3 activation, are also inappropriately activated in GBMs. We have recently demonstrated aberrant expression of endogenous regulators of the JAK/STAT-3 pathway. Protein Inhibitor of Activated STAT-3 (PIAS3), a negative regulator of activated STAT-3, is absent or expressed at very low levels in GBMs, and CK2, a protein kinase important for potentiating JAK1, JAK2 and STAT-3 activation, is over-expressed in GBMs. The premise of this application is that the JAK/STAT-3 signaling axis is inappropriately activated in the context of GBMs, and that therapeutic intervention will be of clinical benefit to patients with GBMs. Aim 1 will characterize the JAK/STAT-3 Molecular Profiles in Primary GBM Tumors and Impact on Patient Survival. The activational status of this pathway in glioma tissues will be examined, and associations with PIAS3 and/or CK2, with tumor grade, GBM subtypes (classical, mesenchymal, proneural, neural), and overall patient survival analyzed. Aim 2 will elucidate the Mechanism(s) by Which the JAK/STAT-3 Pathway is activated in GBMs, and test the influence of AZD1480, a potent inhibitor of activated JAK1/JAK2, in glioma xenografts and glioblastoma stem cells (GBM-SC). Analysis of how xenograft and GBM-SC gene expression and/or behavior is affected when PIAS3 or CK2 expression is modulated will also be examined. Aim 3 will elucidate the Role of Activated JAK/STAT-3 on Gliomagenesis in Vivo, and the Efficacy of the JAK1/JAK2 Inhibitor AZD1480 in preclinical models of malignant gliomas. Changes in survival rates, tumor growth rates, invasion and angiogenesis for human glioma xenografts treated with AZD1480 alone and in conjunction with temozolomide/radiation will be evaluated. Syngeneic GBM models will also be evaluated. The proposed studies are innovative and novel because they are the first comprehensive analysis of the inter- relationships between JAK1, JAK2, STAT-3, PIAS3 and CK2, and whether their expression levels predict patient survival and/or serve as prognostic factors for GBMs. This analysis of GBM tissue samples, TCGA and Oncomine data, human glioma xenografts, GBM-SC, pre-clinical models of glioma and use of AZD1480 will provide the foundation for proposed therapeutic intervention of the JAK/STAT-3 signaling axis in patients with GBMs. PUBLIC HEALTH RELEVANCE: One critically important signaling pathway gaining interest in the context of GBMs is the JAK/STAT-3 pathway, and we hypothesize that JAKs are novel therapeutic targets in GBMs. We will test for the first time the potent JAK1/JAK2 inhibitor AZD1480: by inhibiting the upstream kinases JAK1 and JAK2, AZD1480 treatment will lead to inhibition of STAT-3 activation, gene expression, and the biological functions that promote and sustain gliomagenesis. Collectively, the results from this proposal will provide a compelling rationale for the use of JAK/STAT-3 inhibitors in clinical trials for patients with GBMs.
描述(由申请人提供):胶质母细胞瘤(GBM)是一种几乎普遍致命的中枢神经系统恶性肿瘤。酪氨酸磷酸化信号通路的组成性激活是癌症(包括GBM)的一个标志。GBM显示信号转导和转录激活因子-3(STAT-3)的水平升高和持续激活,STAT-3是一种驱动调节抗凋亡反应、血管生成、细胞增殖和信号转导的基因表达的转录因子。重要的是,STAT-3最近被证明是GBM攻击性的主要调节剂。Janus激酶1(JAK 1)和JAK 2是STAT-3激活的关键酪氨酸激酶,在GBM中也被不适当地激活。我们最近已经证明了JAK/STAT-3通路的内源性调节因子的异常表达。活化的STAT-3的蛋白抑制剂(PIAS 3),活化的STAT-3的负调节剂,在GBM中不存在或以非常低的水平表达,并且CK 2,一种对增强JAK 1、JAK 2和STAT-3活化重要的蛋白激酶,在GBM中过表达。本申请的前提是JAK/STAT-3信号传导轴在GBM背景下被不适当地激活,并且治疗干预将对GBM患者具有临床益处。目的1将描述原发性GBM肿瘤中JAK/STAT-3分子谱及其对患者生存期的影响。将检查胶质瘤组织中该途径的激活状态,并分析与PIAS 3和/或CK 2、肿瘤分级、GBM亚型(经典、间充质、前神经、神经)和患者总体生存期的相关性。目的2将阐明JAK/STAT-3通路在GBM中被激活的机制,并测试激活的JAK 1/JAK 2的有效抑制剂AZD 1480在胶质瘤异种移植物和胶质母细胞瘤干细胞(GBM-SC)中的影响。还将检查当PIAS 3或CK 2表达被调节时异种移植物和GBM-SC基因表达和/或行为如何受到影响的分析。目的3将阐明激活的JAK/STAT-3在体内胶质瘤发生中的作用,以及JAK 1/JAK 2抑制剂AZD 1480在恶性胶质瘤临床前模型中的疗效。将评价AZD 1480单独治疗和与替莫唑胺/放射联合治疗的人胶质瘤异种移植物的存活率、肿瘤生长率、侵袭和血管生成的变化。还将评价同基因GBM模型。所提出的研究是创新的和新颖的,因为它们是JAK 1、JAK 2、STAT-3、PIAS 3和CK 2之间的相互关系的第一次全面分析,以及它们的表达水平是否预测患者生存和/或作为GBM的预后因素。对GBM组织样品、TCGA和Oncomine数据、人胶质瘤异种移植物、GBM-SC、胶质瘤临床前模型和AZD 1480的使用的分析将为GBM患者中JAK/STAT-3信号传导轴的拟议治疗干预提供基础。 公共卫生关系:在GBM的背景下,一个非常重要的信号通路是JAK/STAT-3通路,我们假设JAK是GBM的新治疗靶点。我们将首次测试有效的JAK 1/JAK 2抑制剂AZD 1480:通过抑制上游激酶JAK 1和JAK 2,AZD 1480治疗将导致抑制STAT-3激活,基因表达以及促进和维持胶质瘤形成的生物学功能。总的来说,本提案的结果将为在GBM患者的临床试验中使用JAK/STAT-3抑制剂提供令人信服的依据。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Etty N Benveniste其他文献

Etty N Benveniste的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Etty N Benveniste', 18)}}的其他基金

Project 2: Validating the JAK/STAT Pathway as a Novel Therapeutic Strategy in PD
项目 2:验证 JAK/STAT 通路作为 PD 的新型治疗策略
  • 批准号:
    9976624
  • 财政年份:
    2018
  • 资助金额:
    $ 30.4万
  • 项目类别:
Project 2: Validating the JAK/STAT Pathway as a Novel Therapeutic Strategy in PD
项目 2:验证 JAK/STAT 通路作为 PD 的新型治疗策略
  • 批准号:
    10469388
  • 财政年份:
    2018
  • 资助金额:
    $ 30.4万
  • 项目类别:
Targeting the JAK/STAT-3 Pathway Signaling Axis in Glioma
靶向胶质瘤中的 JAK/STAT-3 通路信号轴
  • 批准号:
    8434816
  • 财政年份:
    2012
  • 资助金额:
    $ 30.4万
  • 项目类别:
Targeting the JAK/STAT-3 Pathway Signaling Axis in Glioma
靶向胶质瘤中的 JAK/STAT-3 通路信号轴
  • 批准号:
    8618781
  • 财政年份:
    2012
  • 资助金额:
    $ 30.4万
  • 项目类别:
Training Program in Brain Tumor Biology
脑肿瘤生物学培训计划
  • 批准号:
    7436144
  • 财政年份:
    2007
  • 资助金额:
    $ 30.4万
  • 项目类别:
Therapeutic Intervention of the JAK/STAT Pathway for Neuroinflammation
JAK/STAT 通路对神经炎症的治疗干预
  • 批准号:
    8630636
  • 财政年份:
    2007
  • 资助金额:
    $ 30.4万
  • 项目类别:
Training Program in Brain Tumor Biology
脑肿瘤生物学培训计划
  • 批准号:
    8871806
  • 财政年份:
    2007
  • 资助金额:
    $ 30.4万
  • 项目类别:
Training Program in Brain Tumor Biology
脑肿瘤生物学培训计划
  • 批准号:
    7638542
  • 财政年份:
    2007
  • 资助金额:
    $ 30.4万
  • 项目类别:
Expression and Function of SOCS Proteins in Glial Cells
SOCS 蛋白在胶质细胞中的表达和功能
  • 批准号:
    7313365
  • 财政年份:
    2007
  • 资助金额:
    $ 30.4万
  • 项目类别:
Expression and Function of SOCS Proteins in Glial Cells
SOCS 蛋白在胶质细胞中的表达和功能
  • 批准号:
    7769836
  • 财政年份:
    2007
  • 资助金额:
    $ 30.4万
  • 项目类别:

相似海外基金

Mechanisms that underlie the life/death decisions in a cell that activated apoptotic caspases
细胞中激活凋亡半胱天冬酶的生/死决策的机制
  • 批准号:
    10607815
  • 财政年份:
    2023
  • 资助金额:
    $ 30.4万
  • 项目类别:
Nuclear and chromatin aberrations during non-apoptotic cell death in C. elegans and mammals
线虫和哺乳动物非凋亡细胞死亡过程中的核和染色质畸变
  • 批准号:
    10723868
  • 财政年份:
    2023
  • 资助金额:
    $ 30.4万
  • 项目类别:
Non-apoptotic functions of caspase-3 in neural development
Caspase-3在神经发育中的非凋亡功能
  • 批准号:
    10862033
  • 财政年份:
    2023
  • 资助金额:
    $ 30.4万
  • 项目类别:
Apoptotic Donor Leukocytes to Promote Kidney Transplant Tolerance
凋亡供体白细胞促进肾移植耐受
  • 批准号:
    10622209
  • 财政年份:
    2023
  • 资助金额:
    $ 30.4万
  • 项目类别:
Design of apoptotic cell mimetic anti-inflammatory polymers for the treatment of cytokine storm
用于治疗细胞因子风暴的模拟凋亡细胞抗炎聚合物的设计
  • 批准号:
    22H03963
  • 财政年份:
    2022
  • 资助金额:
    $ 30.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Identifying the mechanisms behind non-apoptotic functions of mitochondrial matrix-localized MCL-1
确定线粒体基质定位的 MCL-1 非凋亡功能背后的机制
  • 批准号:
    10537709
  • 财政年份:
    2022
  • 资助金额:
    $ 30.4万
  • 项目类别:
Environmental Carcinogens Induce Minority MOMP to Initiate Carcinogenesis in Lung Cancer and Mesothelioma whileMaintaining Apoptotic Resistance via Mcl-1
环境致癌物诱导少数 MOMP 引发肺癌和间皮瘤的癌变,同时通过 Mcl-1 维持细胞凋亡抵抗
  • 批准号:
    10356565
  • 财政年份:
    2022
  • 资助金额:
    $ 30.4万
  • 项目类别:
Targeting apoptotic cells to enhance radiotherapy
靶向凋亡细胞以增强放射治疗
  • 批准号:
    10708827
  • 财政年份:
    2022
  • 资助金额:
    $ 30.4万
  • 项目类别:
Activation of non-apoptotic cell death by the DNA damage response
DNA 损伤反应激活非凋亡细胞死亡
  • 批准号:
    10388929
  • 财政年份:
    2022
  • 资助金额:
    $ 30.4万
  • 项目类别:
Role of natural immunity to self apoptotic exosomes in maintaining immune homeostasis
对自凋亡外泌体的自然免疫在维持免疫稳态中的作用
  • 批准号:
    RGPIN-2021-03004
  • 财政年份:
    2022
  • 资助金额:
    $ 30.4万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了